Theralux™ ATIR Feasible Strategy for Mismatched Stem Cell Transplantation
(NL version) | go backKiadis Pharma B.V. has announced Phase I data suggesting that it’s investigational Theralux™-ATIR technology reduced the risk of acute graft-versus-host disease among blood cancer patients who received donor lymphocyte infusions (DLI) following mismatched stem cell transplantation. Data were presented during the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH).
Click here to read the full press release
May 29th 2008
Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
(NL version)
Apr 15th 2008
Mar 25th 2008
Promising clinical data from Kiadis Pharma’s lead product ATIR™ presented by NIH investigators
(NL version)
Feb 22nd 2008
Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™
(NL version)
Jan 31st 2008
Dec 19th 2007
Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc
(NL version)
Dec 14th 2007
ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments
(NL version)
Nov 28th 2007
Nov 23rd 2007
Nov 19th 2007
Kiadis Pharma continues to provide Rhitol to participating physicians during completion of current clinical study
(NL version)
Nov 7th 2007
Oct 10th 2007
Aug 31st 2007
Aug 17th 2007
Jul 21st 2007
Jul 9th 2007
Jun 26th 2007
Mar 28th 2007
Feb 12th 2007
Jan 19th 2007
Dec 13th 2006
Dec 12th 2006
Dec 11th 2006
Nov 28th 2006
